Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to compounds with cytotoxic activity consisting of cyclopeptides containing the RGD sequence and derivatives of camptothecin, methods for the preparation thereof, their use as medicaments and compositions containing them.
• the compounds described in the present invention are endowed with both high affinity for integrins ⁇ v 63 and ⁇ v ⁇ s and selective cytotoxic activity on human cell lines at micromolar concentrations.
• Chemotherapeutic anticancer agents are the drugs with the most restrictive therapeutic window. In fact, since their cytotoxic activity is non-selective they may indiscriminately damage all the cells of the body with which they come into contact.
• the compounds according to the present invention yield medicaments with fewer and less severe side effects.
• the object of the present invention are derivatives of 7-t- butoxyiminomethylcamptothecin conjugated to cyclopeptide derivatives containing the RGD sequence.
• the resulting molecules possess unaltered both the cytotoxic properties of the original camptothecins and integrin binding properties with affinity comparable to that observed with the non-conjugated cyclopeptides.
• the result of this combination is to favour the concentration of the cytotoxic agent in those cells that most express integrins of the ⁇ v 63 and a v 6s type (homing).
• the cytotoxic agent exerts its intracellular activity in the conjugated and/or free form through enzymatic or hydrolytic action.
• the main object of the present invention are therefore compounds of Formula (I)
• Ri is the U-X-Y group, in which: U is either absent or one of the following groups -COCHR1.0NH- or CON[(CH2)n2NHR 7 ]-CH2-, where Rio is H or is selected from the group consisting of : linear or branched C1-C4 alkyl, optionally substituted with C ⁇ -Ci4 aryl or an amino-alkyl C1-C4; R7 is H or linear or branched C1-C4 alkyl; n 2 is an integer number from 2 to 6; X is absent or is H or is a group selected among the following: -COCHR3NH-, -COCHR 6 (CH2)n 3 R 4 -, -R4-CH2(OCH 2 CH2)n4OCH 2 R4-, -R 4 (Q)R 4 -, -R 5 [Arg-NH(CH2)n5CO]n6R5-, -R 5 -[N-guanidinopropyl- Gly n
• the present invention comprises the use of compounds with the above- mentioned compounds of Formula (I) as active ingredients for medicaments useful as topoisomerase I inhibitors.
• medicaments useful as topoisomerase I inhibitors useful as topoisomerase I inhibitors.
• topoisomerase I inhibition we mention parasitic or viral infections.
• the compounds of Formula (I) compounds are also useful for the preparation of medicaments for the treatment of tumours and the metastatic forms thereof.
• the present invention also comprises pharmaceutical compositions containing compounds of Formula (I) as active ingredients, in mixtures with at least one pharmaceutically acceptable vehicle and/or excipient.
• the compounds according to the present invention are the result of the condensation of 7-t-butoxyiminomethylcamptothecin, functionalised in position 20, with a cyclopeptide containing the Arg-Gly-Asp (RGD) sequence.
• This structural combination has the advantage of favouring the concentration of the cytotoxic agent (camptothecin) in the cells that most express integrins of the ⁇ v 63 and a v 6s type.
• the cytotoxic agent exerts its activity in the conjugated and/or free form through enzymatic or hydrolytic action.
• One initial group of preferred compounds consists of the compounds of Formula (I) where U and/or X are not absent.
• the preferred compounds according to the present invention are the following:
• the compounds of Formula (I) which are the object of the present invention are prepared by means of the condensation of 7- t-butoxyiminomethylcamptothecin (indicated as “7-t-but-CP”), possibly functionalised via a suitable bridge (indicated as "U ⁇ -X ⁇ ”) , with a cy- clopeptide derivative (indicated as "Yi").
• the condensation reactions can be carried out according to one of the following reaction schemes: 7-t-but-CP + U1-X1-Y1 or 7-t-but-CP-Ui + X1-Y1 or 7-t-but-CP-U ⁇ -X ⁇ + Y ⁇ or 7-t-but-CP + Ui + Xi + Yi or 7-t-but-CP-U ⁇ + X ⁇ + Y ⁇ ; where 7-t-but-CP represents 7-t-butoxyiminomethylcamptothecin, Ui, Xi and Yi represent respectively the groups U, X and Y as defined in Formula I, eventually appropriately functionalised and/or protected so that the conjugated compounds of Formula I are obtained.
• the cyclopeptides Yi can be prepared according to conventional peptide synthesis techniques, as described in examples 1 to 6.
• the peptide synthesis can be accomplished either in the solid phase or in solution.
• the desired cyclopeptide Once the desired cyclopeptide has been obtained, it will be used in the condensation reaction in its protected form, and the protector groups will be removed only after obtaining the final compound.
• the deprotec- tion is done using known methods, e.g. acid conditions by means of the use of pure trifluoroacetic acid or in the presence of chlorinated organic solvents.
• the compounds described in the present invention are topoisomerase I inhibitors and are therefore useful as medicaments, particularly for the treatment of diseases that benefit from the inhibition of said topoisomerase.
• the compounds according to the present invention exhibit antiproliferative activity, and therefore are used for their therapeutic properties, and possess physicochemical properties which make them suitable for formulation in pharmaceutical compositions..
• compositions contain at least one formula (I) compound as an active ingredient, in an amount such as to produce a significant therapeutic effect.
• the compositions covered by the present invention are entirely conventional and are obtained using methods that are common practice in the pharmaceutical industry. According to the administration route opted for, the compositions will be in solid or liquid form and suitable for oral, parenteral or intravenous administration.
• the compositions according to the present invention contain, along with the active ingredient, at least one pharmaceutically acceptable vehicle or excipient.
• Formulation adjuvants such as, for example, solubilising agents, dispersing agents, suspension agents or emulsifying agents may be particularly useful.
• the compounds of Formula (I) can also be used in combination with other active ingredients, such as, for example, anticancer agents or other drugs with antiparasitic or antiviral activity, both in separate forms and in a single dosage form.
• active ingredients such as, for example, anticancer agents or other drugs with antiparasitic or antiviral activity, both in separate forms and in a single dosage form.
• the compounds according to the present invention are useful as medicaments with anticancer activity, e.g. in non-microcytoma and small- cell lung cancer, or in colorectal or prostate cancer, glioblastoma and neuroblastoma, cervical cancer, ovarian cancer, gastrointestinal carcinoma, carcinoma of the liver, Kaposi's sarcoma, renal carcinoma, sarcoma and osteosarcoma, testicular carcinoma, carcinoma of the breast, carcinoma of the pancreas, melanoma, carcinoma of the urinary bladder and of the head and neck.
• anticancer activity e.g. in non-microcytoma and small- cell lung cancer, or in colorectal or prostate cancer, glioblastoma and neuroblastoma, cervical cancer, ovarian cancer, gastrointestinal carcinoma, carcinoma of the liver, Kaposi's sarcoma, renal carcinoma, sarcoma and osteosarcoma, testicular carcinoma, carcinoma of the breast, carcinoma of the pancreas, melanoma
• One of the advantages afforded by the compounds according to the present invention is the combination of antitopoisomerase activity, proper to the camptothecin portion of the molecule, and the integrin inhibiting activity, provided by the cy- clopeptide portion of the molecule.
• the result is the possible combined action of the compounds according to the present invention which will be favourably received in the oncological sector by the experts operating in that sector.
• the cyclopeptide portion containing the Arg- Gly-Asp sequence, not only directs the molecule against tumours expressing integrins, but, once the target has been reached, is capable of exerting multiple functions, ranging from the internalisation of the cytotoxic portion of the molecule to integrin inhibiting activity, with the resulting advantages, particularly in terms of the inhibition of tumour angiogenesis.
• the cyclopeptide portion, once separated from the camptothecin portion is also capable of exerting its action at a distance from the site of the tumour, and therefore the compounds according to the present invention also prove useful in the prevention or treatment of metastatic forms.
• the medicaments which are the object of the present invention can also be used in the treatment of parasite diseases.
• Aad aminoadipic acid
• NMP N-methyl-pyrrolidone
• TBTU tetrafluoroborate-O-benzotriazol-l-yl-tetramethyluronium
• TFA trifluoroacetic acid
• the linear peptide was synthesized in solid phase as described in example 1, inserting Fmoc-N-Me-Phe-(4-Pht-N-CH 2 )-COOH as the third amino acid, prepared as described above.
• the deprotections of N-Fmoc-terminal on resin were carried out with 30% diisopro- pylamine (300 eq) in solution in DMF (owing to the presence of phthalimide).
• 500 mg of the peptide were dissolved hot in 10 ml of absolute EtOH, to which 0.9 ml of a solution of NH2- NH2 H2O 1 M in ethanol was added.
• the crude product was recovered by evaporating the organic phase and purified by flash chromatography (mobile phase: CHCi3-MeOH 7:3 + 1% AcOH); the fractions containing the product were pooled, washed with water, dehydrated and brought to dryness, and yielded a residue of 157 mg of pure product.
• the purified ⁇ v 63 receptor (Chemicon, cat. CC1020) was diluted in buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 1 mM MnCk) at a concentration of 0.5 ⁇ g/ml. An aliquot of 100 ⁇ l was added to 96-well plates and incubated overnight at +4°C. Plates were washed once with buffer (50 mM Tris, pH 7,4, 100 mM NaCl, 2 mM CaCb, 1 mM MgCh, 1 mM MnC , 1% bovine serum albumin) and then incubated for another 2 hours at room temperature.
• buffer 50 mM Tris, pH 7,4, 100 mM NaCl, 2 mM CaCb, 1 mM MgCh, 1 mM MnC , 1% bovine serum albumin
• the purified a v 6s receptor (Chemicon, cat. CC1020) was diluted in buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 1 mM MnCk) at a concentration of 1 ⁇ g/ml. An aliquot of 100 ⁇ l was added to 96-well plates and incubated overnight at +4°C. Plates were washed once with buffer (50 mM Tris, pH 7.4, 100 mM NaCl, 2 mM CaCb, 1 mM MgC , 1 mM MnCi2, 1% bovine serum albumin) and then incubated for another 2 hours at room temperature.
• buffer 50 mM Tris, pH 7.4, 100 mM NaCl, 2 mM CaCb, 1 mM MgC , 1 mM MnCi2, 1% bovine serum albumin
• the affinity of the products for vitronectin receptors was expressed as IC50 value ⁇ SD, i.e. as the concentration capable of inhibiting 50% of the specific radioligand-receptor binding.
• IC50 value was elaborated using "ALLFIT" software.
• camptothecin-RGD conjugates for vitronectin ctyBa and civBs receptors
• the sulphoro- damine B test was used.
• PC3 human prostate carcinoma, A498 human renal carcinoma, A2780 human ovarian carcinoma cells and NCI-H460 non-small cell lung carcinoma were used.
• A2780, NCI-H460 and PC3 tumor cells were grown RPMI 1640 containing 10% fetal bovine serum (GIBCO), whereas A498 tumor cells were grown in EMEM containing 10% fetal bovine serum (GIBCO).
• Tumor cells were seeded in 96-well tissue culture plates (Corning) at approximately 10% confluence and were allowed to attach and recover for at least 24 h. Varying concentrations of the drugs were then added to each well to calculate their IC50 value (the concentration which inhibits the 50% of cell survival). The plates were incubated for 72 h at 37 °C or 2 h followed by 72 h of recovery. At the end of the treatment, the plates were washed by removal of the surnatant and addition of PBS 3 times. 200 ⁇ l PBS and 50 ⁇ l of cold 80%TCA were added. The plates were incubated on ice for at least 1 h. TCA was removed, the plates were washed 3 times for immersion in distilled-water and dried on paper and at 40°C for 5 min.
• IC50 value the concentration which inhibits the 50% of cell survival
• the conjugate ST2670 showed the most potent cytotoxic activity on A2780 ovarian tumor cells with an IC50 value of 0.4 ⁇ M. Moreover, the conjugate ST2670 showed a comparable cytotoxicity to that observed with ST2677 (free camptothecin) on tumor cells (Table 3). The conjugate ST2671 also revealed a potent cytotoxicity on PC3 tumor cells comparable to that found with the free camptothecin ST2676.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Oncology (AREA)
• Molecular Biology (AREA)
• Epidemiology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Virology (AREA)
• Communicable Diseases (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Peptides Or Proteins (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (2)

Family

ID=35124315

Family Applications (1)

Country Status (12)

Cited By (2)

Families Citing this family (1)

Family Cites Families (3)

• 2004
  • 2004-05-13 IT IT000242A patent/ITRM20040242A1/it unknown
• 2005
  • 2005-04-28 CA CA002562569A patent/CA2562569A1/en not_active Abandoned
  • 2005-04-28 CN CNA2005800152130A patent/CN101065150A/zh active Pending
  • 2005-04-28 WO PCT/IT2005/000245 patent/WO2005110486A2/en not_active Ceased
  • 2005-04-28 AU AU2005243883A patent/AU2005243883A1/en not_active Abandoned
  • 2005-04-28 EP EP05743414A patent/EP1747020A2/en not_active Withdrawn
  • 2005-04-28 JP JP2007512729A patent/JP2007537243A/ja not_active Withdrawn
  • 2005-04-28 MX MXPA06012885A patent/MXPA06012885A/es not_active Application Discontinuation
  • 2005-04-28 BR BRPI0511077-7A patent/BRPI0511077A/pt not_active IP Right Cessation
  • 2005-04-28 US US11/596,016 patent/US7589099B2/en not_active Expired - Fee Related
  • 2005-05-04 TW TW094114400A patent/TW200538123A/zh unknown
  • 2005-05-12 AR ARP050101934A patent/AR049337A1/es not_active Application Discontinuation

Also Published As

Similar Documents

Legal Events